The role of dapoxetine hydrochloride on-demand for the treatment of men with premature ejaculation

• Published in: Scientific reports Vol. 4; no. 1; p. 7269
• Main Authors: De Hong, Cao, Ren, Liu Liang, Yu, Huang, Qiang, Wei
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.12.2014; Nature Publishing Group
• Subjects: 631/154/1438; 692/699/2768/515; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antidepressants; Benzylamines - administration & dosage; Benzylamines - adverse effects; Clinical trials; Comorbidity; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions - epidemiology; Drug-Related Side Effects and Adverse Reactions - etiology; Ejaculation; Evidence-Based Medicine; Humanities and Social Sciences; Humans; Internationality; Latency; Literature reviews; Male; Middle Aged; multidisciplinary; Naphthalenes - administration & dosage; Naphthalenes - adverse effects; Patient Satisfaction - statistics & numerical data; Premature Ejaculation - epidemiology; Premature Ejaculation - prevention & control; Prevalence; Risk Factors; Science; Serotonin uptake inhibitors; Serotonin Uptake Inhibitors - administration & dosage; Serotonin Uptake Inhibitors - adverse effects; Treatment Outcome; Young Adult
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/srep07269

Premature ejaculation (PE) is the most common male sexual dysfunction. Dapoxetine hydrochloride, belonging to a class of drugs known as selective serotonin reuptake inhibitors or, was the first drug originally approved for the on-demand treatment of men with PE. We aimed to compare the intravaginal ejaculatory latency time (IELT), patient-reported global impression of change (PGIC) and adverse effect (AE) incidence associated with the use of dapoxetine (30 mg and 60 mg) versus placebo and evaluate the differences in administering 60 mg versus 30 mg as on-demand medical oral therapy for the treatment of PE via a literature review and meta-analysis. Relevant randomized controlled trials (RCTs) were identified from PubMed, EMBASE and Cochrane Central Register of Controlled Trials (Cochrane Library) databases. Ultimately, a total of seven RCTs with 8039 patients were included. Our meta-analysis demonstrated that dapoxetine (in the 30 mg and 60 mg subgroup) resulted in significantly higher IELT, PGIC and AE incidence relative to the placebo, with higher proportions observed for 60 mg versus 30 mg of dapoxetine administration. The most common AEs were mild and tolerable. We conclude that dapoxetine (particularly the 60 mg dosage) may be considered a safe and effective drug for patients with PE.